LBA
ALDX icon

Letko, Brosseau & Associates’s Aldeyra Therapeutics ALDX Stock Holding History

Letko, Brosseau & Associates’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.2K Hold
17,300
– – ﹤0.01% 98
2025
Q4 		$89.6K Hold
17,300
– – ﹤0.01% 98
2025
Q3 		$90.3K Hold
17,300
– – ﹤0.01% 95
2025
Q2 		$66.3K Hold
17,300
– – ﹤0.01% 93
2025
Q1 		$99.5K Hold
17,300
– – ﹤0.01% 85
2024
Q4 		$86.3K Buy
+17,300
New +$88.8K ﹤0.01% 97

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Letko, Brosseau & Associates's ALDX Position: Q1 2026 in Review

Letko, Brosseau & Associates held its Aldeyra Therapeutics (ALDX) position steady in Q1 2026 at 17,300 shares worth $29.2K. The position accounts for ﹤0.01% of the portfolio, ranked #98.

Letko, Brosseau & Associates first reported a position in ALDX in Q4 2024 and has held it in 6 quarters since. The position peaked at $99.5K in Q1 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Letko, Brosseau & Associates held 17,300 shares of Aldeyra Therapeutics worth $29.2K as of Q1 2026.
  • Letko, Brosseau & Associates left its Aldeyra Therapeutics share count unchanged in Q1 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #98 holding.
  • Letko, Brosseau & Associates first reported a position in Aldeyra Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Letko, Brosseau & Associates's Aldeyra Therapeutics position peaked at $99.5K in Q1 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.